Clinical Trials Directory

Trials / Conditions / Urethral Cancer

Urethral Cancer

39 registered clinical trials studyying Urethral Cancer5 currently recruiting.

StatusTrialSponsorPhase
RecruitingDESTINY-PANTUMOUR04
NCT07124000
AstraZeneca
RecruitingA Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
NCT05899361
Dana-Farber Cancer InstituteN/A
Recruiting64Cu-GRIP B in Patients With Advanced Malignancies
NCT05888532
Rahul AggarwalPhase 1 / Phase 2
UnknownMRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
NCT03934827
Imperial College LondonPhase 1
RecruitingAnalysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
NCT03291028
Fox Chase Cancer Center
CompletedUC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
NCT02643043
Matthew Milowsky, MDN/A
UnknownFour Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
NCT03296306
Asan Medical CenterPhase 3
RecruitingIntegrated Cancer Repository for Cancer Research
NCT02012699
University of Nebraska
CompletedGemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other So
NCT01352962
National Cancer Institute (NCI)Phase 1
CompletedCarboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patient
NCT01191892
Cardiff UniversityPhase 2
CompletedPazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relaps
NCT01031875
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2
CompletedGemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Loc
NCT01089088
Cardiff UniversityPhase 2
CompletedGemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally
NCT01090466
Cardiff UniversityPhase 1 / Phase 2
Active Not RecruitingBortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
NCT00479128
M.D. Anderson Cancer CenterPhase 1
CompletedSunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
NCT00397488
Memorial Sloan Kettering Cancer CenterPhase 2
UnknownSunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Ur
NCT01118039
Hospital del MarPhase 2
CompletedBiomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
NCT00900276
Wake Forest University Health Sciences
CompletedPemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
NCT00053209
Eastern Cooperative Oncology GroupPhase 2
TerminatedS0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
NCT00087295
SWOG Cancer Research NetworkPhase 2
CompletedShort-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
NCT00082719
M.D. Anderson Cancer CenterPhase 1
CompletedS0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the U
NCT00066612
SWOG Cancer Research NetworkPhase 2
Active Not RecruitingFluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Aden
NCT00082706
M.D. Anderson Cancer CenterPhase 2
CompletedS0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Canc
NCT00045630
SWOG Cancer Research NetworkPhase 2
CompletedS0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Tre
NCT00055835
SWOG Cancer Research NetworkPhase 2
TerminatedS0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
NCT00022633
SWOG Cancer Research NetworkPhase 2
CompletedNeoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radica
NCT00080795
M.D. Anderson Cancer CenterPhase 2
CompletedCisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
NCT00022191
European Organisation for Research and Treatment of Cancer - EORTCPhase 3
CompletedS0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00014144
SWOG Cancer Research NetworkPhase 2
CompletedCombination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Func
NCT00005644
Eastern Cooperative Oncology GroupPhase 2
CompletedCombination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
NCT00014274
European Organisation for Research and Treatment of Cancer - EORTCPhase 2 / Phase 3
CompletedSCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00006351
European Organisation for Research and Treatment of Cancer - EORTCPhase 2
CompletedNitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
NCT00006026
European Organisation for Research and Treatment of Cancer - EORTCPhase 2
CompletedDocetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
NCT00004223
Eastern Cooperative Oncology GroupPhase 2
CompletedCombination Chemotherapy in Treating Patients With Bladder Cancer
NCT00003701
Eastern Cooperative Oncology GroupPhase 3
CompletedSurgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tr
NCT00006111
UNICANCERPhase 2
CompletedTwo-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With A
NCT00003376
Eastern Cooperative Oncology GroupPhase 3
CompletedFluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
NCT00003175
Medical Research CouncilPhase 2
CompletedPiritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00002914
Eastern Cooperative Oncology GroupPhase 2
CompletedCombination Chemotherapy in Patients With Advanced Urinary Tract Cancer
NCT00002684
Memorial Sloan Kettering Cancer CenterPhase 2